Antibiotic-free protein expression platform using pichia pastoris
Isomerase offers a proprietary platform for antibiotic-free protein expression using Pichia pastoris. The platform features auxotrophic mutants and protease knockouts for enhanced protein yield without antibiotics, suitable for commercial bioprocessing applications.
Overview
Isomerase presents an innovative platform for antibiotic-free protein expression using the Pichia pastoris system. This system is designed to enhance the production of recombinant proteins and peptides, bypassing the need for antibiotics. By utilizing Pichia strains with auxotrophic mutations and protease knockouts, the platform not only increases plasmid retention but also minimizes protein degradation, making it ideal for high-yield, scalable production.
Technical specifications
- Auxotrophic mutants: Enable increased plasmid retention without antibiotics.
- Protease knockouts: Reduce protein degradation, enhancing product yield.
- Methanol-free production: Offers a safer, more environmentally friendly process.
- Biopilot facility capabilities: Equipped with 3-7L and 20-30L stirred tank reactors for scalable fermentation.
- Comprehensive downstream processing (DSP): Facilitates both laboratory and pilot-scale operations.
- Technology transfer support: Includes collaboration with CDMOs for large-scale implementation.
Technology readiness level
The technology is currently at TRL 5, having been validated in relevant environments. It is ready to proceed with further optimization and scaling, providing partners with a robust solution for commercial protein production without the need for antibiotics.
About Isomerase
Isomerase is a biotechnology research company and service provider specializing in microbial bioengineering. They leverage a proprietary platform, including the IsoZym bioproduction system, to discover and engineer microbes—such as bacteria and fungi—to produce therapeutics, enzymes, and other biomolecules. The company integrates synthetic biology, bioinformatics, and microbial strain development with advanced analytical chemistry and bioprocessing capabilities to optimize production processes. Their technical expertise spans natural product discovery, metabolic engineering, and the development of recombinant peptides, allowing them to provide end-to-end support from early-stage concept and screening through to process scale-up and commercial readiness.
The company serves partners across the pharmaceutical, biotechnology, and sustainability sectors by helping them access difficult chemical spaces and create more cost-effective, sustainable manufacturing routes. By functioning as an innovation partner, Isomerase addresses the challenges of discovering novel compounds or improving existing bioprocesses for complex products like biocatalytic enzymes and natural product analogues. Their work is supported by an extensive, proprietary collection of microbial strains and state-of-the-art laboratory facilities located in the Cambridge Biomedical Cluster. They provide a collaborative model where partners receive dedicated scientific and business points of contact to ensure accountability and project alignment, helping to bridge the gap between initial discovery and industrial-scale application.
delivered to your inbox.